Skip to content

Study on Registration of Xinyuan Capsule

Study on Registration of Xinyuan Capsule

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03197844
Enrollment
3000
Registered
2017-06-23
Start date
2017-06-23
Completion date
2018-12-31
Last updated
2017-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Disease

Brief summary

The purpose of this study is get to know what and how Xinyuan capsule in hospital results in drug-induced liver injury or adverse drug reactions from a cohort event monitoring as registration research.

Detailed description

In order to improving monitoring drug-induced liver injury or adverse drug reactions of Chinese medicine containing Radix Polygoni Multiflori in hospital, registry study is suitable method in this area. Otherwise, nested case control study is used to find out the mechanism of drug-induced liver injury. Calculate the incidence of drug-induced liver injury or adverse drug reactions is one of the main aims for this study. Safety surveillance on Chinese medicine containing Radix Polygoni Multiflori is an important problem that needs to be sorted out through large sample observational study. According to the relevant regulations of the CFDA, 3000 cases need to be registered at least. The aim population is who using Xinyuan capsule 's with abnormal liver function before medication from June 2017 to December 2018.

Interventions

None listed

Sponsors

Xiyuan Hospital of China Academy of Chinese Medical Sciences
CollaboratorOTHER
China Academy of Chinese Medical Sciences
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Hours to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients using Xinyuan capsule 's with abnormal liver function before medication from June 2017 to December 2018.

Exclusion criteria

* None.

Design outcomes

Primary

MeasureTime frameDescription
Is there any abnormality in liver function test index(ALT、AST、TBil、GGT)after using xinyuan capsule around four weeks later?After using xinyuan capsule around four weeks later.Based on data from the National Center for adverse drug reactions (ADR), Chinese herbal medicine containing Polygonum multiflorum may cause liver damage, but further confirmation is needed.The liver function includes glutamic-pyruvic transaminase,glutamic-oxalacetic transaminase,GGT,TBil.

Secondary

MeasureTime frameDescription
Is there any abnormality in renal function test index(Bun、Cr) after using xinyuan capsule around four weeks later?After using xinyuan capsule around four weeks later.Observation of whether the kidney function damage after treatment.The renal function includes creatinine,usea nitrogen.
Is there any abnormality in ECG after using xinyuan capsule around four weeks later?After using xinyuan capsule around four weeks later.Observation of whether the ECG damage after treatment.ECG is the most common method of detection of myocardial ischemia and the diagnosis of angina pectoris.
Is there any abnormality in basic life sign(body temperature, blood pressure and pulse)during using xinyuan capsule around four weeks?During using xinyuan capsule around four weeks.Observation of whether the basic life sign damage after treatment.In the medical care system, body temperature, blood pressure and pulse are the most important and basic three physiological parameters of the vital signs.

Contacts

Primary ContactYanming Xie, BA
datamining5288@163.com86-13911112416
Backup ContactLianxin Wang, doctor
wanglianxin_tcm@126.com86-13521781839

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026